tbuckley/cabot-search huggingface dataset:
<i>History of Nursing</i>. From the earliest times to the present day with special reference to the work of the past thirty years. Edited and in part written by Lavinia L. Dock, R. N., Secretary of the International Council of Nurses, Graduate of Bellevue Training School, New York City. In four volumes. Volumes III and IV with 43 illustrations. (<i>New York and London: G. P. Putnam's Sons, 1912</i>.)
Journal: American Journal of Psychiatry (1913)
Recurrence score and clinicopathologic characteristics of TAILORx participants by race and ethnicity.
Authors: Maria M Zlobinsky Rubinstein, Robert James Gray, Joseph A. Sparano, JoAnne Zujewski, Timothy Joseph Whelan, Kathy S. Albain, Daniel F. Hayes, Charles E. Geyer, Elizabeth Claire Dees, Edith A. Perez, Maccon M. Keane, Carlos Vallejos, Timothy F. Goggins, Ingrid A. Mayer, Adam Brufsky, Deborah Toppmeyer, Virginia G. Kaklamani, James Norman Atkins, Jeffrey L. Berenberg, George W. Sledge
Journal: Journal of Clinical Oncology (2015)

533 Background: Black race is associated with worse outcomes in localized breast cancer. We evaluated the characteristics of patients enrolled in the Trial Assigning Individualized Options for Treatment (TAILORx) by race and ethnicity. Methods: The analysis included 10,071 evaluable patients with Recurrence Score (RS) data. Eligibility criteria included: (1) T1-2, N0 disease, (2) estrogen receptor (ER) and/or progesterone receptor (PR) positive disease that was also HER2/neu negative, (3) age 75 years or younger and medically appropriate for adjuvant systemic chemotherapy. Results: The study population included 8,501 whites (84%), 722 blacks (7%), 423 Asians (4%), and the remainder other/unknown race. With regard to ethnicity, 7,916 were non-Hispanic (79%), 919 were Hispanic (9%), and 1,236 were of unreported ethnicity (12%). There was no significant difference in RS distribution (p = 0.14), median RS (17 vs. 17), and mean RS (19.6 vs. 18.4) in blacks compared with non-blacks. There was likewise no difference in Hispanic vs. non-Hispanic ethnicity for RS distribution (p = 0.53), median RS (17 vs. 17), and mean RS (18.6 vs. 18.4). Blacks were significantly more likely to be younger (39% vs. 30% < 50 years), have larger tumors (37% vs. 31% > 2 cm), poor histologic grade (25% vs. 17%), and PR-negative disease (14% vs. 10%) (Chi square test p < 0.05). Hispanic women were also significantly younger (39% vs. 30% < 50 years), and demonstrated marginal but statistically significant differences in tumor size (34% vs. 31% > 2 cm), histologic grade (20% vs. 18% poor), and PR expression (12% vs. 10% negative) (Chi square test < 0.05). In 974 patients with information on body mass index (BMI), there was no correlation between BMI and RS (r = -0.04). BMI was higher for blacks than whites (medians 31.6 vs. 28.9, p = 0.02, Wilcoxon test), but not in Hispanics. Conclusions: In patients selected for participation in TAILORx there were no significant differences in RS by race, ethnicity, and BMI. When compared to white patients, black and Hispanic patients were significantly younger, had tumors that were larger, and more likely to be associated with poor grade. Clinical trial information: NCT00310180.
Bone morphogenetic protein 7 in dormancy and metastasis of prostate cancer stem-like cells in bone
Authors: Aya Kobayashi, Hiroshi Okuda, Fei Xing, Puspa R. Pandey, Misako Watabe, Shigeru Hirota, Sudha K. Pai, Wen Liu, Koji Fukuda, Christopher Chambers, Andrew Wilber, Kounosuke Watabe
Journal: The Journal of Experimental Medicine (2012)
Mechanism of Digitalis Action on the Heart
Authors: Jan Koch-Weser
Journal: New England Journal of Medicine (1967)

Cellular Mechanisms of ActionMuch of the persistent confusion about the cellular actions of digitalis may be attributed to three factors. First of all, digitalis and related cardio-active steroids exert their therapeutic actions on the heart in a narrow range of concentrations. Many investigators have employed concentrations so high as to be incompatible with cardiac function. In such toxic concentrations the cardiac glycosides have many interesting effects on ion fluxes, on cellular metabolism and on contractile proteins, but such effects need not have much bearing on the mechanism of the therapeutic action. Secondly, almost every biochemical or biophysical effect ever . . .
<i>BJSM</i>reviews: A–Z of nutritional supplements: dietary supplements, sports nutrition foods and ergogenic aids for health and performance Part 5
Authors: L M Castell, L M Burke, S J Stear, L R McNaughton, R C Harris
Journal: British Journal of Sports Medicine (2009)

<h3>Purpose:</h3> Recent evidence documents significant associations between community design, physical activity and obesity when adjusting for demographic covariates. Yet it is well understood that energy imbalance and weight gain are also a function of dietary patterns, and perhaps the degree of access to healthy food choices. <h3>Methods:</h3> The current study builds upon the Atlanta-based SMARTRAQ study of over 10 000 respondents and reports an integrated assessment of obesity impacts of physical activity and food outlet visitation. Respondents in the SMARTRAQ survey aged 25–65 provided BMI, self-reported physical activity levels (IPAQ), demographic factors, and where they went for food over a 2 day period. <h3>Results:</h3> The relative effect of physical activity, neighbourhood walkability, and food outlet visitation on BMI differed significantly across gender and ethnicity. BMI in females increased with fast food and decreased with grocery store visitation and physical activity, but not with walkability or walking. BMI in males was not related to where they went for food but decreased with walking and overall physical activity and with walkability. Fast food visitation was associated with increased BMI in white respondents and grocery store visitation with decreased BMI in black respondents. Meeting moderate activity guidelines was associated with lower BMI in both black and white respondents, yet walking was only significant in predicting reduced BMI in white respondents. <h3>Conclusion:</h3> Obesity influences of physical activity, walkability, and where people go for food differ significantly across gender and ethnicity and offer important policy implications and insights for future research.
New Names
Journal: JAMA (1973)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Poster discussion I
Authors: Di Lisciandrano, T Baldassarri, M Ranzi, Pullan Campanini, Thomas Gao, M Rhodes, G Perucchini, A Lago, J Rhodes
Journal: Gut (1993)

Gastroenterology (1), Surgery (2) and Histopathology (3), University Topical treatment with 5-aminosalicylic acid (5-ASA) is frequently Hospital of Wales, Cardiff and Physiological Sciences (4), given to patients with ileorectal anastomosis (IRA) after colectomy for Newcastle-upon-Tyne, UK ulcerative colitis (UC).5-ASA absorption in this condition has not been investigated.We therefore studied six UC patients with IRA in remission and six healthy volunteers: after at least 48 hours without treatment, half a A continuous layer of adherent mucus gel covers colonic mucosa.Its Pentasa® 4% enema (50 ml) was administered, and heparinized blood thickness may be relevant to mucosal protection and the pathophysiology of samples were taken immediately before administration, after 30 and 60 colonic disease but it has never been measured in man.We sought to identify minutes and then hourly for 8 hours.Urine was collected after. 4.5, 9 and and quantitate this layer as part of ongoing work into the role of mucus in 24 hours.Blood samples were centrifuged immediately.Plasma and urine inflammatory bowel disease (IBD).were stored_ at..0C.5-A&-Aand its major metabolite acetyl 5-ASA (ac.5-Thick mucosal sections taken from fresh colectomy specimens are viewed ASA) were measured by-HPLC.One patient retained the enema less than 5 trne l osan ierse from fresh contraom illuminare this hours, another 7 hours, and the others more than 9 hours.All the controls transversely on an inverse microscope under phase contrast illumination this retained the enema at least 9 hours.Figure 1 shows the mean plasma allows direct measurement of the gel layer. 82specimens were studied: concentra ions of 5-ASAantc ac 5-ASA in.patients and controls.46 from carcinoma, 2 diverticular disease, 1 appendix mass, 1 lipoma, 1.2 17 ulcerative colitis (UC) and 15 Crohn's disease (CD).FIG. 1
LETTER FROM BERLIN.
Authors: None B.
Journal: JAMA (1894)

<h3>On the Production and Application of Curing Serum-Liquids (Heilserum), for Diphtheria. German Surgical Congress.</h3> BerlinW., July, 1894. The Professors Ehrlich, Kossel and Dr. Wasserman, in Berlin, have published a paper on the application of curing serum as invented by Prof. Behring, assistant of Prof. Koch. Behring had undertaken to give an immunity from the diphtheritic poison and after that, to get a serum from the blood of those animals, by which he hoped to protect individuals of the human race against the results of diphtheria as well as to cure the disease when already developed in an individual. Ehrlich, Kossel and Wasserman have followed Behring in his experiments. They always had in view to use the results of their experiments for curative purposes. They experimented on goats. We will say nothing of the technical dates for giving the serum. Two hundred and twenty patients with diphtheria were treated with
Sotalol
Authors: Alastair J.J. Wood, Stefan H. Hohnloser, Raymond L. Woosley
Journal: New England Journal of Medicine (1994)

Sotalol hydrochloride is a potent noncardioselective β-adrenergic-blocking agent devoid of intrinsic sympathomimetic and membrane-stabilizing actions16. Unlike other β-adrenergic-blocking drugs, sotalol (4-(2-isopropylamino-1-hydroxyethyl) methanesulfonanilide hydrochloric acid) prolongs the duration of action potentials recorded in cardiac tissue, increases the refractory period, and lengthens the QT interval on the surface electrocardiogram1,2. It is an effective antiarrhythmic and antifibrillatory agent in patients with various cardiac-rhythm disorders. The drug has been used extensively in Europe and has recently been approved for marketing in the United States as an agent for oral use in patients with life-threatening ventricular tachyarrhythmias. β-Adrenergic AntagonismSotalol is . . .
The Coronary Drug Project
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The future of pediatrics. Implications of the changing environment of medicine. Council on Long Range Planning and Development in cooperation with the American Academy of Pediatrics
Journal: JAMA (1987)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Seeking to end smoking's appeal to women, youth
Authors: P. Gunby
Journal: JAMA (1985)

This will be the first year in US history in which more women will die of carcinoma of the lung than of any other form of cancer. That is the prediction of the president of the American Cancer Society, Robert J. McKenna, MD, clinical professor of surgery, University of Southern California School of Medicine, Los Angeles, and surgical oncologist in private practice. He told a San Diego seminar that the American Cancer Society is going to Congress, the Federal Trade Commission, business and industry, and the public in an intensified campaign against tobacco. Using data from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute, Bethesda, Md, the society is projecting 38,600 deaths from carcinoma of the lung in American women this year. For the first time, this figure is higher than the projected number of deaths (38,400) among US women from carcinoma of the breast.
Handbook of Therapeutics
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The FDA and hypoglycemic drugs
Authors: J. K. Davidson
Journal: JAMA (1975)

THE NELSON Committee hearings in the US Senate (Sept 18 to 20, 1974) explored the<i>safety, effectiveness</i>, and<i>use</i>of hypoglycemic drugs. A dozen witnesses, including the Food and Drug Administration (FDA) Commissioner Dr. Alexander Schmidt, gave testimony concerning the implications of the University Group Diabetes Program (UGDP) articles for medical practice. Concern was expressed because the FDA Bureau of Drugs had not required appropriately written package inserts warning physicians and the drug-consuming public of the dangers inherent in the indiscriminate use of sulfonylureas and phenformin hydrochloride. There was agreement that caloric restriction with weight reduction is the preferred method of treatment for the maturity-onset diabetic who is above ideal body weight, and that such therapy is always safe and with intensive education and follow-up is usually effective. The UGDP investigators ended the<i>tolbutamide</i>(sulfonylurea) study in 1969 and the<i>phenformin</i>study in 1971, when careful statistical analysis showed a death
Unusual Deformity in Aortic Stenosis Preventing Coronary Artery Cannulation
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Herpesviruses and cancer
Authors: C. R. Goodheart
Journal: JAMA (1970)

The herpesviruses form a large group with many common properties. Many animal species have one or more distinct herpesviruses. Strong evidence is available that at least two nonhuman herpesviruses are able to induce malignancy in nonhuman vertebrates, and weak but suggestive evidence exists for four others. There is also suggestive evidence for an association of two herpesviruses with human malignancies. Because proper experiments cannot be done with oncogenic viruses in humans, studies with oncogenic herpesviruses of other animals are extremely important to understanding human cancer.
Autotransfusion and Jehovah's Witnesses
Journal: JAMA (1964)

<h3>To the Editor:—</h3> In a recent "Critique and Cavil" item concerning blood transfusion and Jehovah's Witnesses (<i>JAMA</i><b>188</b>:532 [May 11] 1964), Dr. George X. Trimble named several publications which had commented on autotransfusion, including<i>GP</i>(<b>19</b>:98, 1963). He also stated, "Apparently, officials of Jehovah's Witnesses will sanction a patient receiving a transfusion of his own blood." We do not have available for checking, all the publications Dr. Trimble quotes, but we do have a tear sheet from<i>GP</i>, volume 19, No. 6, which is page 98 of the issue of June, 1959, not 1963. We believe the procedure described therein is the same as that referred to by Dr. Trimble. If we are correct in this conclusion, then we have no objection to this technique if it is carried out as described in the<i>GP</i>write-up. However, we can see no way in which it becomes "apparent" from
Free clinics. A solution that can work ... now!
Authors: K. C. Kelleher
Journal: JAMA (1991)

FREE CLINICS have formed nationwide as a grass-roots effort to provide health care to a largely indigent and disenfranchised target population. Born in the radical 1960s, free clinics have evolved into well-respected health care centers providing outpatient services primarily to the working poor. Their current success is testimony to their broad-based community support and to the voluntarism of the medical community. With no federal support and little local governmental support, there are over 200 free clinics in the United States, many with 15-year histories. They are functioning with little networking and have developed independent solutions to the problem of providing care to the uninsured. These solutions are surprisingly uniform. First, free clinics are based in neighborhoods where there is need. Access and transportation are big problems for the uninsured, and accessibility is limited by any other solution. Familiarity also encourages use. Also, a strong identification occurs with a neighborhood clinic
Prognostic factors associated with short-term survival (STS) in advanced pancreatic cancer (APC): A Canadian multicenter analysis from the CHORD Consortium.
Authors: Miguel Cardoso, Sakshi Mehta, Christina Kim, Dawn Elizabeth Armstrong, Ravi Ramjeesingh, Daniel John Renouf, Shahid Ahmed, Yoo-Joung Ko, Mohammed Harb, Shiying Kong, Winson Y. Cheung, Brandon M. Meyers
Journal: Journal of Clinical Oncology (2019)

e15717 Background: The survival of patients (pts) with APC (locally advanced/metastatic) is slowly improving; however in some pts it remains extremely short. Few studies have evaluated the clinical, pathologic and treatment characteristics associated with STS in APC. Methods: Pts with APC (between 2011-2017) were included in the analysis. Descriptive analyses were conducted for demographic, tumor and treatment characteristics between pts who survived ≤ and &gt; 90 days using Wilcoxon rank-sum test and Chi-square test for continuous and categorical variables respectively. Multivariable logistic regression was performed to identify association between pts’ characteristics and STS. Results: A total of 580 pts were included in the analysis: median age 68, 53% male, 92% metastatic and 53% ECOG 0/1. STS ≤90 days occurred in 152 pts (26.2%), with 65.1% not receiving any chemotherapy. Median overall survival for STS was 49 days vs. 276 for non-STS. At least 1 cycle of chemotherapy was administered to 358 pts; mean duration of 1 st line chemotherapy for pts with STS ≤90 was 1.5(SD 2.5) cycles (N = 53), compared to 7.6(SD 11.1) cycles (N = 305) for pts surviving &gt; 90 days. Prognostic factors associated with STS ≤90 days were neutrophil:lymphocyte ratio, LDH, metastatic disease, ECOG and not receiving chemotherapy (Table). Other clinical factors (BMI, smoking history, diabetes) and laboratory values (platelet, baseline CA19-9, estimated GFR) were not prognostic. Conclusions: In a multicenter database of Canadian academic centers, &lt; 2/3 of pts received at least 1 cycle of chemotherapy. STS ≤90 days occurred most often in pts who did not receive chemotherapy. Prognostic factors associated with STS include routine laboratory values, receipt of chemotherapy, ECOG and the presence of metastatic disease. Further analyses of these factors may help improve survival in APC. [Table: see text]